ARS Pharmaceuticals (SPRY) FCF Margin (2022 - 2026)
ARS Pharmaceuticals' (SPRY) quarterly FCF Margin came in at 198.17% in Q1 2026, up 31398.0% year-on-year from N/an in Q1 2025, and down 28.0% quarter-over-quarter from 154.82% in Q4 2025.
ARS Pharmaceuticals (SPRY) FCF Margin (2022 - 2026) Analysis & Trends
ARS Pharmaceuticals has disclosed FCF Margin across 5 years of filings, most recently posting 198.17% for Q1 2026.
- FCF Margin for Q1 2026 came in at 198.17%, up 31398.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 177.11% (down 15544.0% YoY), and the FY2025 annual result was 203.14%, down 21771.0% from the prior year.
- FCF Margin came in at 198.17% for Q1 2026 at ARS Pharmaceuticals, down from 154.82% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 47.96% in Q4 2024 to a low of 166990.0% in Q2 2023.
- The 5-year median for FCF Margin is 703.77% (2024), against an average of 18389.82%.
- Across the five-year window, FCF Margin plunged 16549151 bps in 2023 and jumped 16555080 bps in 2024, its largest moves.
- ARS Pharmaceuticals' FCF Margin stood at 3044.97% in 2022, then plunged by 5384 bps to 166990.0% in 2023, then surged by 100 bps to 47.96% in 2024, then tumbled by 423 bps to 154.82% in 2025, then fell by 28 bps to 198.17% in 2026.
- The last three FCF Margin figures came in at 198.17% (Q1 2026), 154.82% (Q4 2025), and 127.77% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | ARS Pharmaceuticals | 954.24 Mn | 753.27 Mn | - | -198.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -198.17% |
| Dec 31, 2025 | -154.82% |
| Sep 30, 2025 | -127.77% |
| Jun 30, 2025 | -288.61% |
| Mar 31, 2025 | -512.14% |
| Dec 31, 2024 | 47.96% |
| Sep 30, 2024 | -703.77% |
| Jun 30, 2024 | -1,439.20% |
| Jun 30, 2023 | -166,990.00% |
| Mar 31, 2023 | -63,110.00% |
| Sep 30, 2022 | -3,044.97% |
| Jun 30, 2022 | -1,498.49% |
| Mar 31, 2022 | -1,047.66% |